PRECIGEN, INC.
PRECIGEN, INC. (PGEN): 11 pipeline candidates · ~5 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.6 months
D/E 5.85 · 0% dilution
Lead: Approved
11 candidates
N/A
0 buys · 27 sells (180d)
A transparent, data-derived signal for PRECIGEN, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$7.5M
Quarterly Burn
$43.8M
Runway
4.6 mo
Revenue
$23.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| Fludarabine | Phase 1 |
| papzimeos | Approved |
| PRGN-2009 | Phase 2 |
| PRGN-2012 | Phase 2 |
| PRGN-2012 - Phase I; Dose Level 1 | Phase 1 |
| PRGN-2012 - Phase I; Dose Level 2 | Phase 1 |
| PRGN-2012 - Phase II; Dose Level 2 | Phase 1 |
| PRGN-3005 | Phase 1 |
| PRGN-3006 | Phase 1 |
| PRGN-3007 | Phase 1 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
202
Total value held
$444.7M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 15,223,191 | $58.9M |
| vanguard capital management llc | 14,297,992 | $55.3M |
| state street corp | 10,890,124 | $42.1M |
| diametric capital, lp | 6,801,788 | $26.3M |
| tang capital management llc | 6,417,500 | $24.8M |
| geode capital management, llc | 4,613,429 | $17.9M |
| iridian asset management llc/ct | 3,592,730 | $13.9M |
| boxer capital management, llc | 3,500,000 | $13.5M |
| goldman sachs group inc | 3,350,477 | $13.0M |
| citadel advisors llc | 3,002,283 | $11.6M |
Showing top 10 of 202 institutional holders of PRECIGEN, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PRECIGEN, INC.'s pipeline?
PRECIGEN, INC. (PGEN) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PRECIGEN, INC.'s lead drug candidate?
PRECIGEN, INC.'s most advanced tracked candidate is Fludarabine (Phase 1) for Chronic Lymphocytic Leukemia.
What is PRECIGEN, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PRECIGEN, INC. has approximately 4.6 months of cash runway.
What is PRECIGEN, INC.'s market capitalization?
PRECIGEN, INC.'s market capitalization is approximately $1.7B.
Who is the CEO of PRECIGEN, INC.?
Dr. Helen Sabzevari MPH, Ph.D. is the chief executive officer of PRECIGEN, INC. (PGEN).
Get the full picture on PRECIGEN, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.